Comirnaty

Active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus in individuals ≥6 mth.

IM Individual ≥12 yr 30 mcg/dose: 0.3 mL as single dose & in accordance w/ official recommendations, 5 to <12 yr 10 mcg/dose: 2-dose primary series: 0.3 mL/dose. Administer 2nd dose at least 21 days after 1st dose, 6 mth to <5 yr 3 mcg/dose: 3-dose primary series: 0.3 mL/dose. Administer initial 2 doses as 3 wk apart followed by 3rd dose at least 8 wk after 2nd dose. Booster Administer at least 3 mth after completion of primary series & in accordance w/ official recommendations.

Hypersensitivity.

Appropriate medical treatment & supervision should be available in case of anaphylactic reaction following vaccination. Closely observe patient for at least 30 min following vaccination. Do not give subsequent doses to those who have experienced anaphylaxis to earlier dose. Do not administer intravascularly, SC or intradermally. Possible increased risks of myocarditis & pericarditis. Advise vaccine recipients to promptly seek medical attention if they develop chest pain, shortness of breath or abnormal heartbeats. Possible anxiety-related reactions including dizziness, fainting, palpitations, increased heart rate, BP alterations, shortness of breath, tingling sensations, sweating &/or anxiety; avoid injury from fainting. Postpone vaccination in individuals suffering from acute severe febrile illness or acute infection. Bleeding or bruising may occur in individuals receiving anticoagulant therapy or those w/ thrombocytopenia or any coagulation disorder (eg, haemophilia). Immunocompromised individuals including those receiving immunosuppressant therapy. May not protect all vaccine recipients. May temporarily affect ability to drive or use machines. Pregnancy & lactation. Paed <6 mth.

Headache; diarrhoea; arthralgia, myalgia; pyrexia, fatigue, chills, inj site pain, swelling, redness & tenderness; decreased appetite; irritability. Nausea, vomiting; rash.

Do not mix w/ other vaccines or products in the same syringe. Administer different inj vaccines at different inj sites.

Vaccines, Antisera & Immunologicals

J07BN01 - covid-19, RNA-based vaccine ; Belongs to the class of covid-19 vaccines.

POM